DBV Technologies (DBVT) Equity Average (2016 - 2026)
DBV Technologies (DBVT) reported Equity Average of $188.4 million for Q1 2026, up 1143.23% year-over-year from $15.2 million in Q1 2025, and up 69.95% quarter-over-quarter from $110.8 million in Q4 2025.
DBV Technologies (DBVT) Equity Average (2016 - 2026) Analysis & Trends
DBV Technologies (DBVT) has 11 years of Equity Average data on file, last reported at $188.4 million in Q1 2026.
- Equity Average for Q1 2026 came in at $188.4 million, up 1143.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $188.4 million (up 1143.23% YoY), and the FY2025 annual result was $98.1 million, up 17.07% from the prior year.
- Equity Average grew to $188.4 million in Q1 2026 per DBVT's latest filing, from $110.8 million in the prior quarter.
- Over five years, Equity Average peaked at $228.2 million in Q3 2022 and troughed at $15.2 million in Q1 2025.
- A 5-year average of $123.4 million and a median of $125.9 million in 2024 frame the typical range for Equity Average.
- The sharpest annual moves came in 2025 and 2026: Equity Average plunged 87.97% in 2025, then jumped 1143.23% in 2026.
- A 5-year view of Equity Average shows it stood at $203.3 million in 2022, then plunged by 30.09% to $142.1 million in 2023, then plunged by 71.34% to $40.7 million in 2024, then soared by 172.19% to $110.8 million in 2025, then jumped by 69.95% to $188.4 million in 2026.
- Business Quant data shows DBVT's Equity Average at $188.4 million in Q1 2026, $110.8 million in Q4 2025, and $69.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 21.35 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 516.41 Mn |
| 10 | DBV Technologies | 6.63 Bn | 6.41 Bn | -3.90 Mn | 188.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 188.35 Mn |
| Dec 31, 2025 | 110.83 Mn |
| Sep 30, 2025 | 69.54 Mn |
| Jun 30, 2025 | 44.56 Mn |
| Mar 31, 2025 | 15.15 Mn |
| Dec 31, 2024 | 40.72 Mn |
| Sep 30, 2024 | 66.56 Mn |
| Jun 30, 2024 | 95.37 Mn |
| Mar 31, 2024 | 125.92 Mn |
| Dec 31, 2023 | 142.09 Mn |
| Sep 30, 2023 | 154.12 Mn |
| Jun 30, 2023 | 171.67 Mn |
| Mar 31, 2023 | 186.77 Mn |
| Dec 31, 2022 | 203.25 Mn |
| Sep 30, 2022 | 228.23 Mn |
| Jun 30, 2022 | 163.24 Mn |
| Mar 31, 2022 | 90.67 Mn |
| Dec 31, 2021 | 108.08 Mn |
| Sep 30, 2021 | 129.96 Mn |
| Jun 30, 2021 | 156.10 Mn |